© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | T. Lehtinen
Articles
Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035)
March 01, 2001
ByE. Kimby|C. Geisler|H. Hagberg|H. Holte|T. Lehtinen|C. SundströmRituximab (Rituxan) is approved for use in patients with relapsed and refractory follicular lymphoma. Considering the immune modulating effect of interferon alfa-2a (IFN [Roferon-A]) and its efficacy as a single agent in follicular lymphoma, a